Total
0
Shares
Proteomics International Laboratories (ASX:PIQ) - Managing Director, Dr Richard Lipscombe
Managing Director, Dr Richard Lipscombe
Source: Proteomics
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Proteomics International Laboratories (PIQ) has been awarded a $100,000 voucher to manufacture clinical diagnostic tests in Western Australia
  • The funding from the MTPConnect WA Life Sciences Innovation Hub MTP will go towards producing Proteomic’s PromarkerD blood test, the world’s first predictive diagnostic test of diabetic kidney disease
  • Using the funding, the company will establish manufacturing quality control for PromarkerD in WA over a nine month period, in the hope of supporting future large-scale manufacture of the test for both Australia and the South-East Asia region
  •  Proteomics International last traded at 94 cents on November 2

Proteomics International Laboratories (PIQ) has been awarded a $100,000 voucher to support the manufacture of clinical diagnostic tests in Western Australia.

The funding from the MTPConnect WA Life Sciences Innovation Hub MTP will go towards future production of Proteomic’s PromarkerD blood test, the world’s first predictive diagnostic test of diabetic kidney disease.

PromarkerD is a prognostic test that can predict future kidney function decline in patients with type 2 diabetes, or even no existing diabetic kidney disease. The test system uses a simple blood test to detect early onset of the disease by measuring three serum protein biomarkers and has correctly predicted up to 86 per cent of otherwise healthy diabetics in clinical studies.

Proteomic’s project, entitled ‘Manufacturing the next generation in vitro diagnostic device to predict diabetic kidney disease’, will see the company establish a manufacturing quality control capability for PromarkerD in WA.

In doing so, the company hopes the project will support the future large-scale manufacture of the PromarkerD test for both Australia and the South-East Asia region.

”Ultimately, by enhancing our production capabilities, patients in the region will benefit as they will have easier access to the test,” said Proteomics Managing Director Dr Richard Lipscombe.

The company said the $100,000 voucher will be matched dollar for dollar, with the project to be completed over nine months.

Proteomics International last traded at 94 cents on November 2.

PIQ by the numbers
More From The Market Herald
Rhythm Biosciences (ASX:RHY) - Executive Chairman, Otto Buttula

" Rhythm Biosciences (ASX:RHY) shuffles board

Rhythm Biosciences (RHY) has restructured its board and management team, effective immediately.

" Epsilon Healthcare (ASX:EPN) extends agreement with The Valens Company

Epsilon Healthcare (EPN) has extended its agreement with The Valens Company to January 31, 2022.
Starpharma (ASX:SPL)

" Starpharma’s (ASX:SPL) nasal spray registered for sale in Vietnam

Starpharma’s (SPL) VIRALEZE product has been registered for sale in Vietnam.  
Telix Pharmaceuticals (ASX:TLX) - CEO, Christian Behrenbruch

" Telix Pharmaceuticals’ (ASX:TLX) Illuccix authorised in Brazil

Telix Pharmaceuticals (TLX) has been granted authorisation for Illuccix, the company’s lead prostate cancer imaging product.